PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Liraglutide — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Liraglutide is a glucagon-like peptide-1 analogue given by once-daily subcutaneous injection. · pmid:26132939

History

In the LEADER trial of 9,340 people with type 2 diabetes and high cardiovascular risk, fewer patients on liraglutide than on placebo had cardiovascular death, non-fatal heart attack or non-fatal stroke (13.0% against 14.9%; hazard ratio 0.87). · pmid:27295427

A 56-week trial in 3,731 people with obesity and no diabetes studied the 3.0 mg daily dose alongside lifestyle counselling for weight management. · pmid:26132939

Identity

PubChem CID 16134956: Liraglutide, C172H265N43O51, 3751 g/mol. · pubchem:16134956

CAS registry number 204656-20-2. · pubchem:16134956

Where the evidence actually sits

Established100%

Proportion of the 2 claims about Liraglutide standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. (2015) · establishedLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes. (2016) · established20152016

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Liraglutide yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. · pmid 26132939 · 2015
    • Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. · pmid 27295427 · 2016
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.